Literature DB >> 26924061

Long-term graft outcomes and patient survival are lower posttransplant in patients with a primary renal diagnosis of glomerulonephritis.

Rishi Pruthi1, Mark McClure2, Anna Casula3, Paul J Roderick4, Damian Fogarty5, Mark Harber6, Rommel Ravanan2.   

Abstract

Glomerulonephritis (GN) is the primary diagnosis in 20% to 40% of patients receiving a renal transplant. Here we studied patient survival and graft outcomes in patients with GN transplanted in the UK. UK Renal Registry data were used to analyze patient survival and graft failure in incident transplant patients between 1997 to 2009 who had a diagnosis of primary GN, in comparison to patients transplanted with adult polycystic kidney disease (APKD) or diabetes. Multivariable regression analysis adjusted for age, sex, donor type, ethnicity, donor age, time on dialysis, human leukocyte antigen mismatch, cold ischemic time, and graft failure (for patient survival). Patients were followed up through December 2012. Of 4750 patients analyzed, 2975 had GN and 1775 APKD. Graft failure was significantly higher in membranoproliferative glomerulonephritis (MPGN) type II (hazard ratio: 3.5, confidence interval: 1.9-6.6), focal segmental glomerulosclerosis (2.4, 1.8-3.2), MPGN type I (2.3, 1.6-3.3), membranous nephropathy (2.0, 1.4-2.9), and IgA nephropathy (1.6, 1.3-2.0) compared to APKD. Survival was significantly reduced in patients with MPGN type II (4.7, 2.0-10.8), and those with lupus nephritis (1.8, 1.1-2.9). Overall graft failure for patients with GN was similar to those with diabetes. Thus, in comparison to outcomes in APKD, graft survival is significantly lower in most GNs, with variation in outcomes between different GNs. This information should assist in pretransplant counseling of patients. Further study is required to understand the reduced survival seen in lupus nephritis and MPGN type II, and to improve overall graft outcomes.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APKD; IgA nephropathy; diabetes; glomerulonephritis; membranoproliferative glomerulonephritis (MPGN); systemic lupus erythematosus

Mesh:

Year:  2016        PMID: 26924061     DOI: 10.1016/j.kint.2015.11.022

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides.

Authors:  Tripti Singh; Brad Astor; Weixiong Zhong; Didier Mandelbrot; Arjang Djamali; Sarah Panzer
Journal:  Transplant Direct       Date:  2017-10-18

Review 2.  Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation.

Authors:  Gabriella Moroni; Mirco Belingheri; Giulia Frontini; Francesco Tamborini; Piergiorgio Messa
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

3.  Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry.

Authors:  Wen-Ling Yang; Bhadran Bose; Lei Zhang; Megan Mcstea; Yeoungjee Cho; Magid Fahim; Carmel M Hawley; Elaine M Pascoe; David W Johnson
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

4.  A large, international study on post-transplant glomerular diseases: the TANGO project.

Authors:  Audrey Uffing; Maria José Pérez-Sáez; Gaetano La Manna; Giorgia Comai; Clara Fischman; Samira Farouk; Roberto Ceratti Manfro; Andrea Carla Bauer; Bruno Lichtenfels; Juliana B Mansur; Hélio Tedesco-Silva; Gianna M Kirsztajn; Anna Manonelles; Oriol Bestard; Miguel Carlos Riella; Silvia Regina Hokazono; Carlos Arias-Cabrales; Elias David-Neto; Carlucci Gualberto Ventura; Enver Akalin; Omar Mohammed; Eliyahu V Khankin; Kassem Safa; Paolo Malvezzi; Michelle Marie O'Shaughnessy; Xingxing S Cheng; Paolo Cravedi; Leonardo V Riella
Journal:  BMC Nephrol       Date:  2018-09-12       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.